These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27614395)

  • 21. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer.
    Fukushima H; Moriyama S; Waseda Y; Fukuda S; Uehara S; Tanaka H; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Eur Urol Focus; 2021 Mar; 7(2):366-372. PubMed ID: 31987764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer.
    Chen Z; Ding W; Xu K; Tan J; Sun C; Gou Y; Tong S; Xia G; Fang Z; Ding Q
    PLoS One; 2012; 7(10):e47199. PubMed ID: 23082147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
    Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
    Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    Haas M; Engelmann SU; Mayr R; Gossler C; Pickl C; Kälble S; Yang Y; Otto W; Hartmann V; Burger M; Hartmann A; Breyer J; Eckstein M
    BJU Int; 2024 Aug; 134(2):249-257. PubMed ID: 38409965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables.
    Miyake M; Matsuyama H; Teramukai S; Kinoshita F; Yokota I; Matsumoto H; Shimada K; Kinjyo M; Shimokama T; Okumura K; Yomenori M; Enokida H; Nakagawa M; Nakai Y; Fujimoto K;
    Int J Clin Oncol; 2020 Jul; 25(7):1364-1376. PubMed ID: 32232691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients.
    Ogihara K; Kikuchi E; Yuge K; Ito Y; Tanaka N; Matsumoto K; Miyajima A; Asakura H; Oya M
    Ann Surg Oncol; 2016 May; 23(5):1752-9. PubMed ID: 26671037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of family history among patients with urinary bladder cancer.
    Egbers L; Grotenhuis AJ; Aben KK; Alfred Witjes J; Kiemeney LA; Vermeulen SH
    Int J Cancer; 2015 Mar; 136(5):1117-24. PubMed ID: 24978702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.
    Leo MC; McMullen CK; O'Keeffe-Rosetti M; Weinmann S; Garg T; Nielsen ME
    Urol Oncol; 2020 Feb; 38(2):39.e21-39.e27. PubMed ID: 31711836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
    Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
    Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y
    BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
    Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
    Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
    Wu J; Cheng X; Yang H; Xiao S; Xu L; Zhang C; Huang W; Jiang C; Wang G
    Int Urol Nephrol; 2024 May; 56(5):1627-1637. PubMed ID: 38177927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.